Our internationally recognised publications give you access to the expertise of hundreds of the world’s leading scientists, experts and researchers.

Our unrivalled collection of publications spans evidence-based clinical knowledge, research and regulatory information. The extensive breadth of content on MedicinesComplete supports your decision making, from research to the point of care and provides you with the world’s most trusted resources.

We’re excited to announce the launch of two new resources: Martindale’s ADR Checker, a quick and easy tool to support you when managing patients with adverse drug reactions, and the Palliative Care Formulary, the expert source of drug information in palliative and hospice care.

Subscribe Publication Updates

Publication Updates

13 Jul
Dietary Supplements logo
Dietary Supplements July 2021 Update

This update contains revisions to Hyaluronic acid, Lecithin, Melatonin, Vitamin C, and Vitamin D.

13 Jul
Stockley's Interactions Checker_logo
Stockley’s Interactions Checker July 2021 Update

New and updated interactions now available

For July, 850 new interactions have been added, and 213 existing interactions have been updated.

13 Jul
Palliative Care Formulary July 2021 Update

This update contains 4 revised monographs and 1 discontinued monograph.

The following monographs have been fully revised: Anti-epileptics; Methenamine hippurate; Psychostimulants.

The following monographs have undergone minor revision: Drugs for pruritus.

The following monographs have been discontinued: Carbamazepine.

13 Jul
Handbook on Injectable Drugs logo
ASHP Injectable Drug Information July 2021 Update

This update contains 2 new monographs and 103 revised monographs.

New monographs: Oliceridine Fumarate; Etesevimab

Revised monographs: Tropisetron Hydrochloride; Linezolid; Rocuronium Bromide; Azithromycin; Caffeine Citrate; Dexmedetomidine Hydrochloride; Eptifibatide; Daptomycin; Pantoprazole Sodium; Anidulafungin; Caspofungin Acetate; Micafungin Sodium; Tigecycline; Voriconazole; Esomeprazole Sodium; Moxifloxacin Hydrochloride; Telavancin Hydrochloride; Tranexamic Acid; Posaconazole; Tedizolid Phosphate; Ceftolozane Sulfate-Tazobactam Sodium; Fosaprepitant Dimeglumine; Isavuconazonium Sulfate; Infliximab; Plazomicin Sulfate; Imipenem-Cilastatin Sodium-Relebactam; Bamlanivimab; Casirivimab; Imdevimab; Albumin Human; Amikacin Sulfate; Amphotericin B; Calcium Chloride; Calcium Gluconate; Cefazolin Sodium; Chloramphenicol Sodium Succinate; Clindamycin Phosphate; Colistimethate Sodium; Dexamethasone Sodium Phosphate; Digoxin; Diphenhydramine Hydrochloride; Dobutamine Hydrochloride; Dopamine Hydrochloride; Doxycycline Hyclate; Epinephrine Hydrochloride; Fentanyl Citrate; Gentamicin Sulfate; Haloperidol Lactate; Heparin Sodium; Hyaluronidase; Hydrocortisone Sodium Succinate; Insulin; Ketamine Hydrochloride; Lidocaine Hydrochloride; Magnesium Sulfate; Methylprednisolone Sodium Succinate; Metoclopramide Hydrochloride; Metronidazole; Morphine Sulfate; Naloxone Hydrochloride; Nitroglycerin; Norepinephrine Bitartrate; Papaverine Hydrochloride; Phenylephrine Hydrochloride; Phenytoin Sodium; Polymyxin B Sulfate; Potassium Phosphates; Sodium Bicarbonate; Tobramycin Sulfate; Vancomycin Hydrochloride; Verapamil Hydrochloride; Acyclovir Sodium; Bumetanide; Labetalol Hydrochloride; Protamine Sulfate; Aztreonam; Ceftazidime; Ranitidine Hydrochloride; Vasopressin; Esmolol Hydrochloride; Midazolam Hydrochloride; Ampicillin Sodium-Sulbactam Sodium; Famotidine; Mesna; Enalaprilat; Ondansetron Hydrochloride; Vecuronium Bromide; Ciprofloxacin; Fluconazole; Amiodarone Hydrochloride; Milrinone Lactate; Metoprolol Tartrate; Diltiazem Hydrochloride; Iopamidol; Ketorolac Tromethamine; Piperacillin Sodium-Tazobactam Sodium; Fusidate Sodium; Granisetron Hydrochloride; Propofol; Levofloxacin; Nicardipine Hydrochloride; Cisatracurium Besylate; Fosphenytoin Sodium

13 Jul
Clarity’s Diagnosis and Treatment Guidance July 2021 Update

This update contains 7 significant changes and 9 minor changes.

Significant Changes:
• Vitamin D deficiency in adults — reviewed. A literature search was conducted in February 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic title has been shortened to ‘Vitamin D deficiency in adults’. The recommendations have been updated in line with current evidence in the literature. The recommendation on who should take year-round vitamin D supplementation for the prevention of vitamin D deficiency has been amended, in line with Public Health England (PHE) guidance PHE, 2016 PHE, 2020. The section on Calcium and vitamin D combination products has been removed from the Prescribing information section to avoid repetition with text in the Management section.

• Vitamin D deficiency in children — reviewed. A literature search was conducted in February 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with current evidence in the literature. The recommended dose for vitamin D supplementation for prevention of vitamin D deficiency has been amended in line with the Royal Osteoporosis Society (ROS) publication Vitamin D and bone health: a practical clinical guideline for patient management in children and young people ROS, 2018.

• Contraception – assessment — reviewed. A literature search was conducted in March 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The structure of the topic has been changed. No major changes to the recommendations have been made.

• Contraception – sterilization — reviewed. A literature search was conducted in April 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.

• Whitlow (staphylococcal and herpetic) — reviewed. A literature search was conducted in March 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.

• Anal fissure — reviewed. A literature search was conducted in March 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made.

• Greater trochanteric pain syndrome — reviewed. A literature search was conducted in April 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic.

Minor Changes:
• Coronavirus – COVID-19 — minor update. Storage details for Pfizer BioNtech vaccine has been updated in line with the revised Summary of Product Characteristics, prevalence data have been updated, information on arranging PCR tests and self-isolation has been updated, information about rare thromboembolic events after AstraZeneca COVID-19 vaccine, information about variants of concern, and details of signs and symptoms of the Delta variant have also been added. The section on the Public health response has been removed as well as the information on administering the Pfizer BioNtech vaccine.

• Prostate cancer — minor update. Links to Prostate Cancer UK patient resources updated.

• Irritable bowel syndrome — minor update. Adverse effects for linaclotide have been updated in line with the revised manufacturer’s SPC and a link to the Ovarian cancer topic has been added to the section on differential diagnosis.

• Urinary tract infection (lower) – women — minor update. A typographical error has been corrected.

• Polymyalgia rheumatica — minor update. Hyperlinks to a charity organization have been updated.

• Antenatal care – uncomplicated pregnancy — minor update. Information on the European Health Insurance Card (EHIC) has been replaced with information on the Global Health Insurance Card (GHIC).

• Diabetes – type 2 — minor update. Adverse effects of GLP-1 receptor agonists updated in line with revised manufacturer’s SPC.

• Shingles — minor update. Prescribing information for aciclovir has been clarified.

• Platelets – abnormal counts and cancer — minor update. Family history of cancer added to the assessment of people with thrombocytosis.

13 Jul
British National Formulary for Children logo
BNF for Children July 2021 Update

This update contains 10 significant changes, 1 dose change, 2 new monographs and 1 deleted monograph.

Significant Changes:
• Contraceptives, interactions: updated guidance.

• COVID-19: updated guidance.

• COVID-19 vaccine: updated guidance in-line with Public Health England recommendations.

• Eczema: updated guidance on the management of infection.

• Emergency contraception: updated guidance.

• Levothyroxine sodium: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products [MHRA/CHM advice].

• Oral anticoagulants: updated guidance in overview.

• Rabies vaccine: addition of new guidance for post-exposure management.

• Skin infections, antibacterial therapy: new guidance for the management of secondary bacterial infection of common skin conditions.

• Vitamins: addition of new guidance for vitamin D.

Dose Change:
• Perampanel [update to include dosing in children from 4 years old for treatment of focal seizures and from 7 years old for primary generalised tonic-clonic seizures].

New Monographs:
Ruconest® [conestat alfa].

Ultomiris® [ravulizumab].

Deleted Monograph: Emollient bath and shower products, tar-containing.

For further details on changes in the BNFC click on
https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes

View more